Dapaglifozina na insuficiência cardíaca com fração de ejeção levemente reduzida ou preservada - deliver

Rossi Neto, João Manoel.
Rev. Soc. Cardiol. Estado de Säo Paulo ; 34(1): 15-19, 2024. tab, ilus
Artigo em Português | CONASS, SES-SP, SESSP-IDPCPROD, SES-SP | ID: biblio-1551394

Similares

  1. [Diabetology: what's new in 2023].
  2. Syntheses of SGLT2 Inhibitors by Ni- and Pd-Catalyzed Fukuyama Coupling Reactions.
  3. Looking deeper into the findings of DARE-19: Failure or an open door to future success?
  4. Sodium-Glucose Cotransporter 2 Inhibitors Decrease the Risk of Acute, Severe Illness: Has the Time Come to Administer Them in the Acute Setting?
  5. SGLT-2 inhibitors may increase ultrafiltration in incident peritoneal dialysis patients: a case report.
  6. The Impact of Midodrine on Guideline-Directed Medical Therapy in Patients Admitted With Systolic Heart Failure.
  7. Toxicological assessment of SGLT2 inhibitors metabolites using in silico approach.
  8. Sodium-glucose Cotransporter 2 Inhibitors and Nonalcoholic Fatty Liver Disease.
  9. Reno- and cardioprotective molecular mechanisms of SGLT2 inhibitors beyond glycemic control: from bedside to bench.
  10. Response to letter to the editor regarding the article "SGLT2 inhibitors and cardiovascular and renal outcomes: a meta-analysis and trial sequential analysis" Cardiac, renal protection with SGLT2 inhibitors is evident but not in every diabetic patient.